3/16/22 – RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality March 16, 2022j3ff1 Read More
3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders March 10, 2022j3ff1 Read More
3/7/22 – Proactive Investors: RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022 March 10, 2022j3ff1 Read More
3/7/2022 – Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward March 7, 2022j3ff1 Read More
1/24/2022 – RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain January 24, 2022j3ff1 Read More
12/14/2021 – RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase December 14, 2021j3ff1 Read More
12/6/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81 December 6, 2021j3ff1 Read More
11/30/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81 November 30, 2021j3ff1 Read More
11/29/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury November 29, 2021j3ff1 Read More
